Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Genelux (GNLX) Research & Development (2022 - 2025)

Genelux (GNLX) has 3 years of Research & Development data on record, last reported at $4.1 million in Q3 2024.

  • For Q3 2024, Research & Development rose 43.7% year-over-year to $4.1 million; the TTM value through Sep 2024 reached $16.6 million, up 50.23%, while the annual FY2023 figure was $12.8 million, 40.64% up from the prior year.
  • Research & Development reached $4.1 million in Q3 2024 per GNLX's latest filing, down from $4.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $4.4 million in Q2 2024 and bottomed at $2.5 million in Q4 2022.
  • Average Research & Development over 3 years is $3.5 million, with a median of $3.5 million recorded in 2023.
  • Peak YoY movement for Research & Development: surged 68.56% in 2023, then soared 40.95% in 2024.
  • A 3-year view of Research & Development shows it stood at $2.5 million in 2022, then soared by 68.56% to $4.2 million in 2023, then decreased by 2.62% to $4.1 million in 2024.
  • Per Business Quant database, its latest 3 readings for Research & Development were $4.1 million in Q3 2024, $4.4 million in Q2 2024, and $4.0 million in Q1 2024.